Acesion Seeks Partner For First-In-Class AF Program Following Phase II Success

Shifts Focus To Earlier Program

Having reached proof-of-concept for its first-in-class SK ion channel inhibitor for atrial fibrillation, the Danish firm is on the hunt for a licensee as it moves its attention to its preclinical program for sinus rhythm maintenance.  

Man in business suit climbing up ladder into the sky, success concept
Acesion Is Determined To Advance Its AF Maintenance Program • Source: Shutterstock

Acesion Pharma ApS is on a mission to out-license its lead atrial fibrillation (AF) program for the acute setting after success in a Phase II proof-of-concept trial, a move that would enable the firm to concentrate on developing its earlier AF asset for the broader maintenance setting.

The Phase II data mark the validation of the private Danish firm’s first-in-class approach of inhibiting the SK ion channel, a membrane protein that allows potassium cations to cross the cell membrane

More from Clinical Trials

More from R&D